NOXOPHARM LIMITED — Director's Dealing 2016

Dec 19, 2016

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001. Ame	nded 01/01/11
	Noxopharm Limited (ASX:NOX)
Name of Entity:
	50 608 966 123
ABN:

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Graham Kelly
Date of Last Notice:	18 August 2016

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or Indirect Interest		Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.		-
Date of change		19 December 2016
No. of securities held prior to change		Shares Options Direct 35,000 - Indirect 24,345,000 12,075,000 Total 24,380,000 12,075,000 6,877,568 Performance Shares - Escrowed to 09 Aug 2018
Number acquired		Shares Options Direct - - Indirect 7,030,221 - Total 7,030,221 - a) 152,653 On Market purchase b) 6,877,568 Performance Shares - Escrowed to 09 Aug 2018
Number disposed		Shares Options Direct - - Indirect - - Total - -

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration Note: If consideration is non‐cash, provide details and estimated valuation		a) 152,653 shares $82,127 b) 6,877,568 shares - Milestone achieved, Escrowed to 09 Aug 2018	a) 152,653 shares $82,127 b) 6,877,568 shares - Milestone achieved, Escrowed to 09 Aug 2018	a) 152,653 shares $82,127 b) 6,877,568 shares - Milestone achieved, Escrowed to 09 Aug 2018
No. of securities held after change				Options 12,075,000 - 12,075,000
			Shares	Options
		Direct	35,000	12,075,000
		Indirect	31,375,221	-
		Total	31,410,221	12,075,000
Nature of change Example: on‐market trade, off‐market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy‐back		a) 152,653 On Market purchase b) 6,877,568 Performance milestones achieved – Shares Escrowed to 09 Aug2018

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non‐cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or No contracts detailed above traded during a +closed period where prior written clearance was required? If so, was prior written clearance N/A provided to allow the trade to proceed during this period? If prior written clearance was N/A provided, on what date was this provided?

==> picture [39 x 24] intentionally omitted <==

The CFO Solution

19 December 2016

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011